BREEZE Optional Extension Phase: Long-term safety and efficacy of treprostinil dry powder inhaler (Tyvaso DPI) in pulmonary arterial hypertension

By afschroeder • August 30, 2025

Sahay S, Palevsky H, El-Kersh K, Restrepo-Jaramillo R, Bajwa AA, Desai S, Joly JM, Spikes LA, Eggert MS, Johri S, Shapiro SM, Fisher MR, Shah TG, Ramani GV, Mehta JP, Thrasher CM, Deng C, Smith P, Broderick M, Burger CD. BREEZE Optional Extension Phase: Long-term safety and efficacy of treprostinil dry powder inhaler (Tyvaso DPI) in pulmonary arterial hypertension. Respir Med. 2025 Aug 27;248:108318. doi: 10.1016/j.rmed.2025.108318. Epub ahead of print. PMID: 40882760.

Tags: Cardiology/Epi, Dry powder inhaler, exercise capacity, Prostacyclin dosing, Publications, pulmonary arterial hypertension, Treprostinil, Veterans Administration

Outcome of Patients Presenting With High-Risk Pulmonary Embolism Treated With Mechanical Thrombectomy: A Subgroup Analysis From the STRIKE-PE Study

Sharp ASP, Dohad SY, Weinberg I, Kurzyna M, Davis HC, Stepniewski J, Perkowski PE, Holden A, West FM, Keeling WB, Parikh SA, Moriarty JM. Outcome[...]

Glucagon-Like Peptide 1 Receptor Agonists are Associated With Reduced Risk of Hepatic Encephalopathy in Cirrhosis

Singh V, Wang M, Ebinger J, Velazquez A, Cheng S, Kwan AC, Trivedi HD. Glucagon-Like Peptide 1 Receptor Agonists are Associated With Reduced Risk of[...]

Temporal Trends and Future Projections of Pulmonary Embolism and Top Contributing Causes of death in the United States, 1968-2040: insights from the CDC WONDER database

Khan S, Abbas F, Hassan M, Hussain M, Ahmed M, Ahsan A, Qureshi S, Khalid N, Sajjad A, Baig M, Waqas SA, Fonarow GC, Greene[...]